Research Reference
MariTide
Investigational GIPR antagonist + GLP-1R agonist conjugate for obesity
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
MariTide is an investigational antibody-peptide conjugate combining GIPR antagonism with GLP-1R agonism for obesity. It is not FDA approved.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 10 mg vial. Resulting concentration: 5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 14 mg | 280 units | 2.8 mL | SubQ, monthlyPhase 2 dose |
| 28 mg | 560 units | 5.6 mL | SubQ, monthlyPhase 2 higher dose |
| 42 mg | 840 units | 8.4 mL | SubQ, monthlyPhase 2 higher dose |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
MariTide (LY3841136 / maritide) is an investigational GLP-1/GIP/glucagon tri-agonist (Eli Lilly) in phase 2 trials. It is supplied as a pre-filled pen or lyophilized vial for subcutaneous use, with a long half-life enabling monthly or less-frequent dosing. Compounded research-peptide forms are not FDA-approved.
For a compounded 10 mg vial reconstituted with 2 mL, the concentration is 5 mg/mL; a 14 mg dose draws to 280 units (2.8 mL) — note this exceeds a single vial; real dosing uses higher-concentration pre-filled pens. Compounded forms are not FDA-approved.
Cycling Protocol
Phase 2 trials administer MariTide subcutaneously on a monthly (or less frequent) schedule, with dose escalation over several months, then maintained long-term. No fixed cycle end; studied as chronic monthly therapy.
Routes of Administration
Subcutaneous injection (only established route): Monthly (or less frequent) into the abdomen, thigh, or upper arm. Any time of day, independent of meals.
No oral, intranasal, or intravenous route is established. Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Tri-agonist + Lifestyle | MariTide + diet/exercise | Phase 2 obesity protocol |
Combining multiple GLP-1 agonists is not recommended. MariTide is investigational and not FDA-approved.
Side Effects & Safety
- Nausea, vomiting, diarrhea, constipation — common, usually transient
- Hypoglycemia — risk, especially combined with insulin/sulfonylureas
- Pancreatitis — rare; discontinue if suspected
- Injection-site reactions — common
- Thyroid C-cell tumors — in rodents; avoid in MTC/MEN2 history
MariTide is investigational (phase 2) and not FDA-approved. Compounded research-peptide forms are not FDA-approved.
Research Basis
MariTide is an investigational GLP-1/GIP/glucagon tri-agonist (Eli Lilly), a peptide conjugated for long half-life enabling monthly dosing.
Mechanism: Triple GLP-1, GIP, and glucagon receptor agonism — appetite suppression and insulin secretion (GLP-1), additional metabolic benefit (GIP), and increased energy expenditure / hepatic fat oxidation (glucagon), targeting maximal weight loss.
Clinical evidence: Phase 2 demonstrated significant weight loss; phase 3 planned. Not FDA-approved.
Investigational — not FDA-approved. Compounded research-peptide forms are not FDA-approved.